Transvalvular Mechanical Circulatory Support Reverse Remodels the Ischemic Chronic Failing Heart in an Ovine Model

IF 8.4 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

JACC: Basic to Translational Science Pub Date : 2025-07-01 DOI:10.1016/j.jacbts.2025.01.003

Bart Meyns MD, PhD , Randi J. Parks PhD , Erik Verbeken MD, PhD , Manon van Hecke MD , Steven Jacobs MD, PhD , Magdalena Sikole MD , Charlotte Van Edom MD , Eveline Bennek Schoepping PhD , Piet Claus PhD

引用次数: 0

Abstract

Sixteen sheep with ischemic chronic heart failure were randomized to either 3 months of Impella 5.5 support (Abiomed) or sham. Myocardial reverse remodeling by Impella support was shown by a significant reduction of end-diastolic volume (Impella 22% reduction, and control 5% increase; P = 0.011) and end-systolic volume (Impella 20% reduction, and control 11% increase; P = 0.011). Functional measurements demonstrated improved regional ejection fraction and wall thickening in the viable myocardium of hearts supported with Impella. Supported animals had a significant decrease in wall volume, with less cardiomyocyte hypertrophy than control subjects.

查看原文本刊更多论文

经瓣机械循环支持对绵羊模型缺血性慢性心力衰竭的逆转作用。

16只患有缺血性慢性心力衰竭的羊被随机分为三个月的Impella 5.5支持组（Abiomed）和假组。通过Impella支持的心肌逆转重构表现为舒张末期体积显著减少(Impella减少22%，对照组增加5%；P = 0.011)和收缩期末期容积(Impella减少20%，对照组增加11%；P = 0.011)。功能测量显示，在Impella支持下，心脏存活心肌的局部射血分数和壁增厚有所改善。支持组动物的心肌壁体积明显减小，心肌细胞肥大程度低于对照组。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

JACC: Basic to Translational Science CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

14.20

自引率

1.00%

发文量

161

审稿时长

16 weeks

期刊介绍： JACC: Basic to Translational Science is an open access journal that is part of the renowned Journal of the American College of Cardiology (JACC). It focuses on advancing the field of Translational Cardiovascular Medicine and aims to accelerate the translation of new scientific discoveries into therapies that improve outcomes for patients with or at risk for Cardiovascular Disease. The journal covers thematic areas such as pre-clinical research, clinical trials, personalized medicine, novel drugs, devices, and biologics, proteomics, genomics, and metabolomics, as well as early phase clinical trial methodology.